Aegis Initiates Coverage on NephroGenex (NRX)
Investment analysts at Aegis began coverage on shares of NephroGenex (NYSE:NRX) in a note issued to investors on Tuesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating on the stock.
Shares of NephroGenex (NYSE:NRX) opened at 5.77 on Tuesday. NephroGenex has a 1-year low of $5.00 and a 1-year high of $13.00. The stock’s 50-day moving average is $6.12 and its 200-day moving average is $7.9. The company’s market cap is $49.4 million.
NephroGenex (NYSE:NRX) last announced its earnings results on Wednesday, May 14th. The company reported ($0.37) earnings per share for the quarter.
NephroGenex, Inc is a United States-based drug development company focusing on novel therapies for kidney disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.